Cost of biotech drugs rises


The cost of biotech drugs is rising faster than inflationPeople who rely on a number of specialty biotech drugs to treat their health conditions saw prices rise by 8.7 percent last year, an AARP investigation found.

The cost of these medications, which are often used by the elderly to treat diseases such as cancer and multiple sclerosis, rose at three times the rate of inflation, the advocacy group claimed.

It looked at 144 brand-name and generic drugs that are commonly used by people enrolled in Medicare.

John Rother, AARP executive vice president of policy and strategy, said that specialty drug makers "continue to raise the costs of drugs that have already been developed and tested," which increases the amount paid by patients as well as employers who sponsor health plans.

"Even the most miraculous drug is useless if people can’t afford to take it," he added.

The report also revealed that the price of more than 100 specialty medications jumped by 42.9 percent between 2003 and 2007, while inflation increased by 14.1 percent during that period.

The news comes after a report by Kaiser Family Foundation and the Health Research & Education Trust discovered that U.S. health insurance premiums rose by an average of 5 percent in the past year.

Personal Liberty

Personal Liberty News Desk

Join the Discussion

Comment Policy: We encourage an open discussion with a wide range of viewpoints, even extreme ones, but we will not tolerate racism, profanity or slanderous comments toward the author(s) or comment participants. Make your case passionately, but civilly. Please don't stoop to name calling. We use filters for spam protection. If your comment does not appear, it is likely because it violates the above policy or contains links or language typical of spam. We reserve the right to remove comments at our discretion.